458 related articles for article (PubMed ID: 37088793)
1. Management of chronic myeloid leukemia in 2023 - common ground and common sense.
Senapati J; Sasaki K; Issa GC; Lipton JH; Radich JP; Jabbour E; Kantarjian HM
Blood Cancer J; 2023 Apr; 13(1):58. PubMed ID: 37088793
[TBL] [Abstract][Full Text] [Related]
2. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
[TBL] [Abstract][Full Text] [Related]
3. Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia.
Slezáková K; Mistrík M; Bátorová A
Vnitr Lek; 2020; 66(4):214-224. PubMed ID: 32972178
[TBL] [Abstract][Full Text] [Related]
4. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors.
Haddad FG; Kantarjian H
J Natl Compr Canc Netw; 2024 Feb; 22(1):. PubMed ID: 38394773
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
6. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Jabbour E; Kantarjian H
Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888
[TBL] [Abstract][Full Text] [Related]
9. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
Jabbour E; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):323-34. PubMed ID: 25971713
[TBL] [Abstract][Full Text] [Related]
10. Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.
Monestime S; Al Sagheer T; Tadros M
Am J Health Syst Pharm; 2023 Jan; 80(2):36-43. PubMed ID: 36197958
[TBL] [Abstract][Full Text] [Related]
11. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
Cortes J; Rea D; Lipton JH
Am J Hematol; 2019 Mar; 94(3):346-357. PubMed ID: 30394563
[TBL] [Abstract][Full Text] [Related]
12. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
[TBL] [Abstract][Full Text] [Related]
13. [Research Advance of
Zhou LY; Zhou LY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):585-588. PubMed ID: 37096538
[TBL] [Abstract][Full Text] [Related]
14. [State-of-the-art management of CML in 2015 and future prospects].
Kimura S
Rinsho Ketsueki; 2015 Oct; 56(10):2005-14. PubMed ID: 26458439
[TBL] [Abstract][Full Text] [Related]
15. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
Shih YT; Cortes JE; Kantarjian HM
Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Kantarjian HM; Jabbour E; Deininger M; Abruzzese E; Apperley J; Cortes J; Chuah C; DeAngelo DJ; DiPersio J; Hochhaus A; Lipton J; Nicolini FE; Pinilla-Ibarz J; Rea D; Rosti G; Rousselot P; Shah NP; Talpaz M; Srivastava S; Ren X; Mauro M
Am J Hematol; 2022 Nov; 97(11):1419-1426. PubMed ID: 36054756
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
18. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
Jabbour EJ; Sasaki K; Haddad FG; Issa GC; Garcia-Manero G; Kadia TM; Jain N; Yilmaz M; DiNardo CD; Patel KP; Kanagal-Shamanna R; Champlin R; Khouri IF; Dellasala S; Pierce SA; Kantarjian H
Am J Hematol; 2023 Apr; 98(4):658-665. PubMed ID: 36683287
[TBL] [Abstract][Full Text] [Related]
19. Ever-advancing chronic myeloid leukemia treatment.
Kimura S; Ando T; Kojima K
Int J Clin Oncol; 2014 Feb; 19(1):3-9. PubMed ID: 24258348
[TBL] [Abstract][Full Text] [Related]
20. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
